PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets

Inclusion Criteria: * Healthy adult male and non-pregnant (confirmed by pregnancy test) and non-breastfeeding female participants (18 to 45 years of age at the time of consent). * Willingness to give written consent to participate in the trial, after reading the participant information and consent form and after having had the opportunity to discuss the trial with the Investigator or any delegate. * Ability to read and write and to understand the participant information sheet and the nature of the trial and any hazards from participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial. * Women of childbearing potential (WOCBP) must agree to use a highly effective form of contraception in combination with a barrier method from at least 28 days prior to first dosage to 30 days after last dosage. * Male participants must be willing to ensure the use of condoms from the first dosage to 90 days after last dosage. * Normal body weight range (body mass index (BMI) between 18 and 29.9 kg/ m2) Exclusion Criteria: * Participation in another clinical trial within 3 months prior to the study, or within 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer. (Time calculated relative to the last dose in the previous clinical trial). * Regular daily consumption of more than one liter of xanthine-containing beverages (e.g. chocolates, tea, coffee or cola d…